Cancer Clinical Trials
(101-10) NCT01189851 Intraoperative Radiotherapy (IORT) for the Management
of Carcinoma of the Breast: Use of Mammography, Ultrasonography and Contrast-Enhanced Magnetic
(102-15) Data Registry for Early Stage Breast Cancer: Prospective Data
Collection and Analyses of Wide Local Excisions and Intraoperative Radiotherapy
(131-17) 0C-16-8: A Phase ½ Safety Study of Intratumorally Administered
INT230-6 in Adult Subjects with Advanced Refractory Cancers (Phase 1 clinical
trial appropriate for patients with solid tumors)
(152-17) OC-14-9: A Modular Phase I, Open-Label, Multicenter Study to Assess
Ascending Doses of AZD6738 in Combination with Chemotherapy and/or Novel
Anti Cancer Agents (Phase 1 clinical trial appropriate for patients with
advanced solid malignancies of the breast)
(155-17) 0C 17-1: Phase I Multicenter Study of the Safety of Pharmacokinetics
and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors
and C-Met Dysregulation (Phase 1 clinical trial appropriate for patients
with advanced solid malignancies)
(187-17) 0C-17-11: Phase 1 trial of ZW25 in patients with locally advanced
(unresectable) and/or metastatic HER2-expressing cancers (Phase 1 clinical
trial, appropriate for patients with HER2 expressing cancers.)
(211-17) 0C-17-14: An Open-Label, Non-Randomized, Multicenter Study to
Determine the Pharmacokinetics and Safety of Niraparib Following a Single
Oral Dose in Patients with Advanced Solid Tumors and Either Normal Hepatic
Function or Moderate Hepatic Impairment (Phase 1 Clinical trial appropriate
for patients with advanced solid tumors)
(214-17) OC-17-17: A Phase 1/2 First-in-human Study of BMS-986258 Alone
and in Combination with Nivolumab in Advanced Malignant Tumors (Phase
1/2 clinical trial, appropriate for patients with advanced malignant tumors.)
181-17/0C-14-2: An Open-Label, Phase 2 study of Neratinib in Patients with
Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR,
HER2, HER3) Mutations or EGFR Gene Amplification
157-17/0C-18-2: A Phase I Study of FID-007 in Patients with Advanced Solid Tumors
114-17: A Randomized Phase II/Phase III Study Of Adjuvant Concurrent Radiation
And Chemotherapy Versus Radiation Alone In Resected High-Risk Malignant
Salivary Gland Tumors
112-16: NSABP PROTOCOL B-51/RTOG PROTOCOL 1304 - A Randomized Phase III
Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal
XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary
Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative
Axillary Nodes After Neoadjuvant Chemotherapy
(107-18) 0C-17-5: A Phase 1b/2 Study of BMS-813160 in Combination with
Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors (Phase
1b/2 clinical trial, appropriate for patients with colorectal or pancreatic cancer)
(133-17) 3C-16-5: A Multicenter, Randomized, Open-label, 3-Arm Phase 3
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab
or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab
with a Safety Lead-in of Encorafenib + Binimetinib+ Cetuximab in Patients
with BRAF V600E-mutant Metastatic Colorectal Cancer (Phase 3 clinical
trial, appropriate for patients with colorectal cancer.)
(175-17) A randomized phase II study comparing selumetinib to placebo for
enhancing the clinical efficacy of radioactive iodine (RAI) for recurrent/metastatic
thyroid cancers that retain RAI uptake. Principal Investigator: Michael
J. Demeure, M.D., F.A.C.S., F.A.C.E. Sub-Principal Investigator: George
B. Semeniuk, M.D.
(144-17) 0S-16-18:A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab
(MEDI 4736) in Patients with Advanced Hepatocellular Carcinoma, Pancreatic
Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer (0S-16-18: PIb
(SGI-110) and (MEDI 4736))(Phase 1b clinical trial, appropriate for patients
with advanced liver, pancreatic, bile duct, or gallbladder cancer.)
119-17: Noncoding RNA Biomarkers for Noninvasive and Early Detection of
Pancreatic Cancer
(149-17) Phase II, Double-Blind, Randomized Trial of AVOVA-1 (Autologous
Dendritic Cells Loaded with Autologous Tumor Associated Antigens) vs.
Autologous Peripheral Blood Mononuclear Cells (MC) in Patients with Stage
II or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
after Primary Therapy (Phase II clinical trial, appropriate for patients
with ovarian cancer)
(106-16) 0S-15-5: A Pilot Multi-Arm Study of sEphB4-HSA in Combination
with Different Chemotherapy Regimens in Patients with Specific Advanced
or Metastatic Solid Tumors
(134-17) 0S-16-8:Phase IIa trial of sEphB4-HSA in combination with Anti
PD-1 Antibody (Pembrolizumab, MK-3475) in patients with non-small cell
lung and head and neck cancer
(132-17) 3L-16-4 A Phase Ib/II Clinical Study of BBI608 in Combination
with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients
with Hepatocellular Carcinoma(Phase 1 clinical trial, appropriate for
patients with liver cancer.)
151-17/0C-14-11: A Phase 1, Open-Label, Dose Escalation Study Of Pf-04518600
As A Single Agent And In Combination With Pf-05082566 In Patients With
Selected Locally Advanced Or Metastatic Cancers
(109-17) 2N-16-3: A Phase 2, Fast Real Time Assessment of Combination Therapies
in Immuno-Oncology Stud in Subjects with Advanced Non-small Cell Lung
Cancer (FRACTION-Lung)
(104-17) DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact
Study #4. PI: Binh Ngo, M.D.
135- 17 Caris Molecular Intelligence® and Caris Centers of Excellence
for Precision Medicine NetworkTM Outcomes Associated Repository
136- 17 Caris Molecular Intelligence® and Caris Centers of Excellence
for Precision Medicine Retrospective Outcomes-Associated Database
167-17 Caris ctDNA Validation Project
179-17 Pharmacogenetics Program Pilot program to assess the potential role
of pharmacogenomics to improve drug safety in patients with advanced cancer.
204-17 Advance Treatment of Rare Tumors (tumor and normal tissue collection
for gene expression array, CGH, NGS, and blood for NGS testing)
101-18: Registry of patients in kindreds with germ-line TP53 mutations
(Li-Fraumeni)
(208-17) 0C-17-15: A multicenter, open-label, phase 1b/2 study to evaluate
safety and efficacy of avelumab (MSB0010718C) in combination with chemotherapy
with or without other anti-cancer immunotherapies as first-line treatment
in patients with advanced malignancies (Phase 1b/2 clinical trial, appropriate
for patients with bladder and lung cancers.)
(117-16) Prostate Cancer Active Surveillance: Data Registry for Active
Surveillance Management of Prostate Cancer: Prospective Data Collection
and Analysis
115-16: Stereotactic Body Radiation Therapy (Sbrt) For The Management Of
Carcinoma Of The Prostate: Quality Of Life Data After Primary Stereotactic
Body Radiation Therapy For Localized Prostate Cancer
113-16: Data Registry for Pancreatic Cancer Early Detection: Prospective
Data Collection and Analysis
Click here for a complete, up-to-date list of Cancer Clinical Trials.
For more information call:
949-722-6237